About PierianDx
PierianDx is a company based in Saint Louis (United States) founded in 2014 by Rakesh Nagarajan was acquired by Velsera in January 2023. PierianDx has raised $69.35 million across 8 funding rounds from investors including Inova, RTI International and Orbimed. The company has 234 employees as of April 05, 2024. PierianDx has completed 1 acquisition, including Tute Genomics. PierianDx offers products and services including Clinical Genomics Workspace, Genomics Knowledgebase, Professional Services, and IVD Partnerships. PierianDx operates in a competitive market with competitors including ArcherDX, Personalis, Variantyx, ImaginAb and OncoDNA, among others.
- Headquarter Saint Louis, United States
- Employees 234 as on 05 Apr, 2024
- Founders Rakesh Nagarajan
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Pieriandx India Private Limited
- Date of Incorporation 07 Jan, 2016
- Jurisdiction Pune City, Maharashtra, India
-
Annual Revenue
$6.23 M (USD)50.92as on Mar 31, 2023
-
Net Profit
$469.89 K (USD)60.43as on Mar 31, 2023
-
EBITDA
$921.69 K (USD)57.12as on Mar 31, 2023
-
Total Equity Funding
$69.35 M (USD)
in 8 rounds
-
Latest Funding Round
Not available
-
Investors
Inova
& 9 more
-
Employee Count
234
as on Apr 05, 2024
- Investments & Acquisitions
-
Acquired by
Velsera
(Jan 13, 2023)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of PierianDx
PierianDx offers a comprehensive portfolio of products and services, including Clinical Genomics Workspace, Genomics Knowledgebase, Professional Services, and IVD Partnerships.
Software for analyzing and interpreting genomic data in clinical settings.
Curated resource for accurate variant interpretations and treatment options.
Support for genomics workflows and assay validation processes.
Services for integrating genomic reporting in IVD assays.
People of PierianDx
Unlock access to complete
Funding Insights of PierianDx
PierianDx has successfully raised a total of $69.35M across 8 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in PierianDx
PierianDx has secured backing from 10 investors, including venture fund and institutional investors. Prominent investors backing the company include Inova, RTI International and Orbimed.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields.
|
Locked | Locked | Locked | |
|
Growth-stage US tech companies are funded by Health Catalyst Capital.
|
Locked | Locked | Locked | |
|
ATW Partners is engaged in smart and strategic investing.
|
Locked | Locked | Locked |
Investor details for PierianDx
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by PierianDx
PierianDx has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Tute Genomics.
Investment portfolio details for PierianDx
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Cloud-based genome analysis for precision medicine is provided.
|
Locked | Locked | 2012 | Locked |
Complete acquisition details for PierianDx
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - PierianDx
Detailed financials for PierianDx
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Pieriandx Comparisons
Peer comparison for PierianDx
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of PierianDx
PierianDx operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as ArcherDX, Personalis, Variantyx, ImaginAb and OncoDNA, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Molecular cancer diagnostic products are developed using patented AMP technology.
|
|
| Locked | Locked | Locked |
Genomic sequencing and diagnosis software is provided for healthcare.
|
|
| Locked | Locked | Locked |
Genomics data analysis platform for healthcare diagnostics is offered.
|
|
| Locked | Locked | Locked |
ImaginAb is focused on developing advanced immuno-oncology imaging technologies.
|
|
| Locked | Locked | Locked |
Genomic and theranostic services for oncology precision medicine are delivered.
|
|
| Locked | Locked | Locked |
Provider of test panels for personalized cancer therapies
|
Detailed competitors of PierianDx
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Pieriandx
Complete news archive for PierianDx
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about PierianDx
PierianDx was founded in 2014 and raised its 1st funding round 1 year after it was founded.
PierianDx is headquartered in Saint Louis, United States. It is registered at Saint Louis, Missouri, United States.
PierianDx is a funded company, having raised a total of $69.35M across 8 funding rounds to date.
As of Apr 05, 2024, the latest employee count at PierianDx is 234.
Annual revenue of PierianDx is $6.23M as on Mar 31, 2023.
PierianDx was founded in 2014 in Saint Louis, United States, within the genetic testing sector. Patient-specific diagnoses and treatments for multiple diseases are delivered based on individual DNA analysis. Operations are supported by a proprietary cloud-based Clinical Genomicist Workstation software, which manages next-generation sequencing across six phases: case accessioning, sequencing, analysis, draft report, final report, and electronic health record integration.
PierianDx's top competitors include Personalis, ImaginAb and OncoDNA.
PierianDx offers Clinical Genomics Workspace, Genomics Knowledgebase, Professional Services, and IVD Partnerships.
PierianDx has made 1 acquisition, including Tute Genomics.
PierianDx has 10 investors. Key investors include Inova, RTI International, Orbimed, ARUP Laboratories, and Velsera.